Methods of treatment
AssigneeBow River LLC
InventorsSundar Srinivasan, Christina Chow Wallen
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.
Claims25
A method of treating a disease or disorder with a tyrosine kinase inhibitor in a patient in need thereof, wherein the patient is treated with a strong CYP3A4 inhibitor, comprising:
- a. discontinuing the strong CYP3A4 inhibitor treatment;
- b. delaying administering, for about 3 to about 5 half-lives of the strong CYP3A4 inhibitor after discontinuing the strong CYP3A4 inhibitor treatment, a dose of the tyrosine kinase inhibitor that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor;
- and then
- c. administering the dose of the tyrosine kinase inhibitor that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor;
- wherein the strong CYP3A4 inhibitor is posaconazole, and the disease or disorder is not cancer.
A method of treating a disease or disorder in a patient in need thereof, with a tyrosine kinase inhibitor, wherein the patient is treated with a strong CYP3A4 inhibitor, comprising:
- (a) stopping the strong CYP3A4 inhibitor treatment;
- (b) delaying administering a dose of the tyrosine kinase inhibitor that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor until at least 3 days after stopping the strong CYP3A4 inhibitor in step (a), and then
- (c) administering the dose of the tyrosine kinase inhibitor that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor;
- wherein the strong CYP3A4 inhibitor is posaconazole, and the disease or disorder is not cancer.
Dependencies are inferred from the claim text.